铼-186（锡）羟乙膦酸盐治疗疼痛性骨转移瘤：20例激素抵抗性前列腺癌患者的初步临床经验

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

作者信息

Maxon H R, Schroder L E, Thomas S R, Hertzberg V S, Deutsch E A, Scher H I, Samaratunga R C, Libson K F, Williams C C, Moulton J S

机构信息

Department of Radiology, Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, OH 45267-0577.

出版信息

Radiology. 1990 Jul;176(1):155-9. doi: 10.1148/radiology.176.1.1693784.

DOI:10.1148/radiology.176.1.1693784

PMID:1693784

Abstract

Rhenium-186(tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in areas of osseous metastases in a manner similar to that of standard bone-scanning agents. It also emits beta particles with sufficient energy to be therapeutically useful. A single intravenous injection of about 33 mCi (1,221 MBq) was given to each of 20 elderly patients with advanced skeletal metastases from hormonally resistant prostate cancer. Prompt, significant relief of pain occurred 80% of the time with no significant side effects and only minimal, transient marrow toxicity. Re-186(Sn) HEDP appears to be a useful new agent for the palliation of painful osseous metastases in prostate cancer.

摘要

铼-186（锡）羟乙二膦酸盐（HEDP）是一种新型放射性药物，它在骨转移区域的定位方式与标准骨扫描剂类似。它还发射出具有足够能量的β粒子，可用于治疗。对20名患有激素抵抗性前列腺癌晚期骨转移的老年患者每人静脉注射约33毫居里（1221兆贝可）。80%的患者疼痛迅速得到显著缓解，且无明显副作用，仅有轻微、短暂的骨髓毒性。铼-186（锡）HEDP似乎是缓解前列腺癌骨转移疼痛的一种有用新药。